NYSE: CHEChemed Revenue
Chemed revenue was $2.49B for the trailing 12 months ending Mar 31, 2025, with 10.3% growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $646.9M, up 1.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CHE annual revenue was $2.4B, with 7.4% growth year-over-year.
CHE past revenue growth
How has CHE's revenue growth performed historically?
Company
8.52%
Industry
7.91%
Market
20.27%
CHE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CHE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CHE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
CHE revenue history
Current Revenue
$2.5B
Current Earnings
$308.7M
Current Profit Margin
12.4%
CHE's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when CHE announces revenue.
CHE Revenue History By Year
| CHE Yearly Revenue | CHE Revenue | CHE Change | CHE Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $2.43B | $166.87M | +7.37% |
| 2023-12-31 | $2.26B | $129.45M | +6.06% |
| 2022-12-31 | $2.13B | -$4.30M | -0.20% |
| 2021-12-31 | $2.14B | $59.68M | +2.87% |
| 2020-12-31 | $2.08B | $141.03M | +7.27% |
| 2019-12-31 | $1.94B | $155.91M | +8.75% |
| 2018-12-31 | $1.78B | $115.92M | +6.96% |
| 2017-12-31 | $1.67B | $89.84M | +5.70% |
| 2016-12-31 | $1.58B | $33.49M | +2.17% |
| 2015-12-31 | $1.54B | $87.11M | +5.98% |
| 2014-12-31 | $1.46B | $42.95M | +3.04% |
| 2013-12-31 | $1.41B | -$16.71M | -1.17% |
| 2012-12-31 | $1.43B | $74.07M | +5.46% |
| 2011-12-31 | $1.36B | $75.43M | +5.89% |
| 2010-12-31 | $1.28B | $90.31M | +7.59% |
| 2009-12-31 | $1.19B | $41.30M | +3.59% |
| 2008-12-31 | $1.15B | $48.88M | +4.44% |
| 2007-12-31 | $1.10B | $81.47M | +8.00% |
| 2006-12-31 | $1.02B | $102.62M | +11.20% |
| 2005-12-31 | $915.97M | $181.09M | +24.64% |
| 2004-12-31 | $734.88M | $474.10M | +181.80% |
| 2003-12-31 | $260.78M | $7.09M | +2.79% |
| 2002-12-31 | $253.69M | -$84.22M | -24.92% |
| 2001-12-31 | $337.91M | -$17.40M | -4.90% |
| 2000-12-31 | $355.31M | -$90.29M | -20.26% |
| 1999-12-31 | $445.60M | $64.32M | +16.87% |
| 1998-12-31 | $381.28M | $39.55M | +11.57% |
| 1997-12-31 | $341.73M | $40.52M | +13.45% |
| 1996-12-31 | $301.21M | $30.76M | +11.38% |
| 1995-12-31 | $270.45M | -$374.58M | -58.07% |
| 1994-12-31 | $645.03M | N/A | N/A |
Chemed Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.